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Background: Chikungunya virus (CHIKV) is an arthropod-borne Togavirus belonging to the genus Alphavirus that is 
responsible for sporadic worldwide outbreaks of Chikungunya fever, an acute febrile illness often associated with 
severe polyarthralgia. In Kenya, Chikungunya virus is of great epidemiological concern, with the last major outbreak 
occurring in 2016 in North Eastern Kenya. Reliable detection of CHIKV infections is key to controlling this re-emerging 
pathogen, for which no cure currently exists.  Current diagnostic methods for CHIKV employ a combination of tests, 
particularly immunologic, serologic or virologic techniques.  However, the independent scientific reviews on the 
validity and sensitivity of currently available commercial assays have been conflicting. 
Objective: This study aimed to develop and validate a dromedary antibody-based enzyme linked immunosorbent 
assay for detecting Chikungunya virus infections.  
Methods: To produce sufficient antigen for camel immunization, Chikungunya virus (strain Lamu 33) was propagated 
in confluent C6-36 E2 cells using Cytodex microcarrier system. Purified and inactivated CHIKV immunogen was used 
to inoculate two camels reared at the University of Nairobi farm in Kibwezi, Kenya. Camel serum samples collected 
over the entire immunization period were assayed for the presence of anti-Chikungunya IgG by indirect ELISA. 
Purification of camel Heavy Chain IgG antibodies was performed by lectin affinity chromatography on protein A and 
protein G-Sepharose columns; then conjugated with horse radish peroxidase (HRP). The HRP-conjugated camel Heavy 
Chain IgG2 and IgG3 were optimized for ELISA, with optical density measured using a microplate reader set at 492nm.   
A total of 188 human sera samples were assayed using the developed dromedary-based enzyme linked 
immunosorbent assay to determine Chikungunya virus infections.     
Results: The sensitivity of the dromedary HCAb IgG2 assay was 91.3% (95% CI: 0.831 - 0.994); while that for HCAb 
IgG3 assay was 95.7% (95% CI: 0.898 - 1.01).  The specificity of HCAb IgG2 assay was 92.3% (95% CI: 0.879 - 0.967); 
while the specificity of HCAb IgG3 method was 90% (95% CI: 0.851 - 0.949). For HCAb IgG2 and IgG3 based assays, 
the positive predictive values were 79.2% and 75.8 % respectively; while the negative predictive values were 97% 
and 98.4% for HCAb IgG2 and IgG3 based assays respectively. 
Conclusion: The camel antibody based assay was found to be reliable assay with very good sensitivity and specificity, 
and can be deployed for detection of Chikungunya virus infections. 
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1. Introduction 
Chikungunya virus (CHIKV) is an arthropod-borne 
Alphavirus responsible for sporadic outbreaks of 
Chikungunya  fever in Kenya and globally (Powers and 
Logue, 2007; Leparc-Goffart et al, 2014; Weaver, 2014; 
Staples and Fischer, 2014; WHO, 2016).  The virus is 
transmitted to humans through the bite of infected 
mosquitoes of the genus Aedes– mainly Aedes aegypti 
and Aedes albopictus (Jupp and McIntosh, 1988). Clinical 
illness is characterized by onset of fever, headache, 
fatigue, back and joint pain, myalgia and maculopapular 
rash (Staples et al, 2009). There are no vaccines or 
antiviral medication yet available for treatment of 
Chikungunya  fever (Thiboutot et al, 2010; WHO, 2016). 
Reliable detection of CHIKV infections is key to 
controlling this re-emerging pathogen, for which no 
cure currently exists. CHIKV infections are detected by 
either virologic methods which determine infectivity of 
the virus isolated from a specimen on indicator cells, 
molecular methods that detect of viral RNA or serologic 
methods that detect CHIKV-specific antibodies or 
antigens. The detection method applied is majorly 
determined by the time during which the clinical 
sample is taken. (Cavrini et al, 2009; Staples et al, 2009). 
In 2008, real-time assays became commercially 
available in limited markets. However, the independent 
scientific reviews on the validity and sensitivity of these 
commercial assays have been conflicting. Polymerase 
Chain Reaction technique has the advantage of being 
specific, sensitive and fast, but is only useful during the 
acute stages of infection (Pfeffer et al, 2002). 
Immunofluorescence assays are sensitive and specific 
but lack the ability to quantify antibodies. Enzyme-
linked immunosorbent assays which detect anti-CHIKV 
Ig M and Ig G antibodies have been developed but their 
sensitivities have not been validated. The sensitivity of 
rapid dip-stick variations of the CHIKV ELISA has not 
been well characterized, and these tools are not widely 
available. (Lakshmi et al, 2008; Litzba et al, 2008; 
Rianthavorn et al, 2010; Yap et al, 2010). Virus isolation 
is very sensitive but cannot correctly identify the virus 
isolated from clinical samples, and so other 
confirmatory techniques have to be employed (Cavrini 
et al, 2009). This calls for further research into the 
development of more efficient and robust tools. 
Dromedary Heavy Chain Antibodies (HCAbs) can offer 
an efficient approach to detection of CHIKV as their 
unique homodimeric structure that lacks light chains 
confers to them special characteristics of high solubility, 
remarkable thermal and chemical stability, coupled 
with high affinity to their cognate antigens (Van der 
Linden et al, 1999; Dumoulin et al, 2002). In this study, 
we sought, therefore, to develop an antigen detection 
ELISA and an IgM capture ELISA based on dromedary 
antibodies for the detection of Chikungunya virus 
infections. 
2. Materials and Methods 
2.1 Preparation of viral immunogen 
Inactivated Chikungunya virus (strain Lamu 33) was 
used for camel immunization. Virus stocks were 
prepared in Vero cells (American Type Culture 
Collection - ATCC, CCL81) in 75 cm2 culture flasks 
(NUNC, Roskilde, Denmark) before upscaling in spinner 
bottle cultures containing cytodex microcarrier beads 
covered with monolayers of C6-36 cells (ATCC No. CRL-
1660). Infected culture fluid was concentrated in  
polyethylene glycol and purified by sucrose gradient 
ultracentrifugation at 48384g using a Beckman Coulter, 
Optima L-90K ultracentrifuge (Beckman, CA, USA) for 
16 hr at 4oC (Bundo and Igarashi, 1983). Virus 
concentration was determined as total protein 
concentration using a GeneQuantPro UV 
Spectrophotometer according to the manufacturer’s 
protocol (Amersham, Buckinghamshire, UK). 
2.2 Generation of camel anti-CHIKV antibodies 
Each camel was immunized with a priming dose of 2 mg 
formaldehyde-inactivated CHIKV antigen emulsified in 
complete Freund’s adjuvant via subcutaneous injection 
in a total combined injection volume of 5 ml (1 ml per 
site). Booster doses were administered four times, four 
weeks apart, using 1 mg inactivated CHIKV antigen 
emulsified in incomplete Freund’s adjuvant.  
2.3 Assessment of antibody titres 
Camel serum samples collected over the entire 
immunization period were assayed for the presence of 
anti-Chikungunya  IgG by indirect ELISA. Each well of a 
96-well flat-bottomed ELISA plate (Maxisorp, Nalge 
Nunc Intl, Rocksilde, Denmark) was coated with 100 µl 
of purified Chikungunya virus Lamu33 (250 ng/100 µl) 
diluted in ELISA coating buffer (0.05 M carbonate-
bicarbonate buffer, pH 9.6) and the plate incubated at 
4°C overnight. The wells were blocked with 4% Block 
Ace (Yukijirushi, Sapporo, Japan) for 1 hr at room 
temperature and washed with PBS containing 0.05% 
Tween 20 (PBS-T, pH 7.2). The serum samples were 
diluted in PBS and assays done in triplicate. A hundred 
microlitres of 1:4000 diluted Horseradish Peroxidase-
conjugated rabbit anti-camel antibody (Antibodies 
Online.com, Steinheim, Germany) was added to the 
wells and incubated for 1 hr at 37 °C before developing 
colour using the substrate solution (0.5 mg/ml O-
phenylenediamine dihydrochloride (Sigma-Aldrich, St. 
Louis, MO, USA)). The reaction was stopped after 1 hr 
incubation.  The optical density (OD) of each well was 
measured at 492 nm using an ELISA Reader (Multiscan 
EX reader, Thermo Scientific, Massachusetts, USA) with 
Ascent software version 2.6. 
2.4 Purification of camel anti-Chikungunya 
antibodies 
Purification of camel IgG antibodies was performed 
sequentially by ammonium sulphate precipitation  and 
lectin affinity chromatography on  protein A and protein 
G-Sepharose columns according to the method of 
Hamers-Casterman et al, (1993). 
2.5 Characterization of camel anti-Chikungunya  
HCAbs 
The concentration of the purified antibody fractions 
was determined by a UV visible spectrophotometer 
(GeneQuantPro, Amersham, Buckinghamshire, UK) 
according to manufacturer’s instructions. The purity of 
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the heavy chain antibodies was analyzed by sodium 
dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blot. For Western Blot, the gel was layered 
against a polyvinylidene difluoride (PVDF) membrane 
and electroblotted for 1hr 30 min in 1 x Tris Buffered 
Saline (TBS) buffer (Trizma base 6.05g, glycine 30g, 
methanol 200 ml, 1800ml double distilled water) using 
a Bio-Rad mini-gel blotting device according to the 
manufacturer’s instructions. The PVDF membrane was 
blocked using 4% Block Ace at 4°C overnight and 
washed thrice at 10 min interval with wash buffer (1 x 
TBS containing 0.1% tween 20) (TBS-T). The membrane 
was incubated at room temperature for 2 hr in 15 ml of 
HRP-conjugated anti-VHH antibody diluted 3000 x in 
TBS-T containing 10% blocking solution followed by 
three washes. Colour of the bands was developed by 
incubating the membrane in a chemiluminescent 
reagent (GE Healthcare, Uppsala, Sweden) according to 
the manufacturer’s instructions before capturing the 
image on an ImageQuant LAS 500 chemiluminescent 
machine (GE Healthcare, Uppsala, Sweden) using QA 
LAS 500 control software version 1.0. 
2.6 Labelling of anti-Chikungunya HCAbs with 
horse-radish peroxidase 
Conjugation of the HCAbs to HRP was carried out by a 
modification of the method of Nakane and Kawaoi 
(1974). Three milligrams of peroxidase dissolved in 3 
mL of double distilled water was mixed with  0.6 ml of 
freshly prepared 0.1M sodium periodate (NaIO4) (Wako, 
Osaka, Japan) for 2 hr at room temperature. The 
mixture was dialyzed overnight at 4 °C against sodium 
acetate buffer, pH 4.4. Each of camel anti-CHIKV IgG2 
and IgG3 was dialyzed against 10 mM sodium carbonate 
buffer, pH 9.5, overnight at 4 °C.  
The dialyzed IgGs were each added to the HRPO and 
mixed at room temperature for 2 hr before addition of 
freshly prepared sodium tetrahydroborate (NaBH4) 
(Wako, Osaka, Japan) and mixing for a further 2hr at 4 
°C. The conjugated antibodies were dialyzed against 
PBS overnight at 4oC. Unconjugated HRP was removed 
by ammonium sulphate precipitation of conjugated 
antibodies and centrifugation at 4355 g (Avanti J-26 XP 
centrifuge, Beckman, California, USA) for 15 min at 4 °C. 
The precipitate was dissolved in 3 ml of PBS and 
dialyzed against PBS overnight before addition of 
bovine serum albumin and a Peroxidase Conjugate 
Stabilizer. 
 2.7 HCAb-based CHIKV antigen detection ELISA 
Wells of a 96-well ELISA plate were each coated with 
100μl of 20μg/ml purified rabbit anti-CHIKV polyclonal 
IgG, blocked and washed. 100μl of serially diluted 
100μg/ml inactivated CHIKV was dispensed into 
duplicate wells and the plates incubated for 1 hr at 37 
°C. After washing, 100μl of optimized dilutions of the 
hrp-conjugated camel IgG2 and IgG3 were dispensed 
into respective wells.  The plates were further incubated 
for one hour at 37 °C,  washed, and 100μl of the 
substrate solution added, followed by 1 hr incubation in 
the dark.   
The colour reaction was stopped by addition of 100μl of 
stop solution. Optical density was measured using an 
ELISA Reader set at 492nm.  The procedure was 
repeated several times (n=6) over a two-month period 
using spiked samples to determine inter- and intra-
assay variations. 
2.8 Chikungunya IgM Capture ELISA 
Samples for analysis 
Archived patient sera used in the study were collected 
during the CHIKV outbreak in 2004/5 in Kenya’s Lamu 
and Comoros Islands and preserved in liquid nitrogen at 
the Kenya Medical Research Institute’s Centre for 
Virology Research. 
IgM Capture ELISA 
Wells of two 96-well microtitre plates were coated with 
100 μl (5.5 µg/100 μl ) of goat anti-human IgM (μ-chain 
specific) (Capel ICN Pharmaceuticals, Aurora, USA) 
diluted in ELISA coating buffer and incubated at 4°C 
overnight. All wells were blocked with 4% Block Ace 
and the plates incubated at room temperature for one 
hour before washing with PBS-T.  
Patient sera predetermined to be IgG negative were 
diluted 100 x in PBS-T and 100 μl of each sample 
dispensed into duplicate wells of each plate before 
incubating the plates for 1 hr at 37 °C and washing as 
described. A sample known to contain IgM antibodies 
against CHIKV and one negative for Ig M antibodies 
were each included in each plate as positive and 
negative controls respectively. The assay antigen 
(CHIKV ICF) was diluted in PBS to get 100 Elisa units 
and 100 μl dispensed into all wells. Dilutions of 1:500 
for both hrp- conjugated IgG2 and hrp-conjugated -IgG3 
were prepared in PBS-T and 100 μl of each added to 
respective wells. Colour was developed by adding the 
substrate solution and incubating for 1 hr in the dark, 
the reaction was stopped and the optical density (OD) of 
each well was measured at 492 nm.   
To validate the diagnostic potential the developed 
camel-based IgM Capture ELISA, 188 patient sera 
samples were tested using CDC IgM Capture ELISA as 
the reference standard. The analytical sensitivity, 
specificity and predictive values of the test were 
determined. 
2.9 Data analysis 
ELISA titration curves were generated in GraphPad 
Prism 7.0 (GraphPad Software Inc, La Jolla, CA, USA). 
Sensitivity, specificity, positive predictive values (PPV) 
and negative predictive values (NPV) and their 95% 
confidence intervals (CIs) were determined. 95% 
confidence intervals were calculated using the formula 
P ± 1.96 √P (1-P)/N, where P is the sensitivity or 
specificity, and N is the number of samples from 
participants infected with Chikungunya virus.  Paired t 
test was used to calculate statistical significance at 
p<0.05. 
2.2 Ethical considerations 
Ethical approval for use of experimental animals and 
patient samples was granted by the Kenyatta National 
Hospital and University of Nairobi Ethics Review 
Committee (Ref No: KNH-ERC/A/132). 
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3. Results  
Generation of dromedary heavy chain antibodies 
against Chikungunya virus 
Anti-CHIKV antibodies were produced in two camels 
following immunization with CHIKV antigen and 
antibody titres was determined by indirect IgG ELISA. In 
both animals, the antibody titres increased after each 
booster dose and declined after the fourth dose.  The 
male camel produced consistently higher antibody titre 
over the immunization period (p < 0.05). Overall, strong 
immune responses were demonstrated by both camels 
which enabled harvesting of adequate amounts of IgG 
antibodies (Figure 1). 
Purification and characterization of camel 
antibodies  
In order to obtain pure IgG sub-classes, serum 
immunoglobulins were precipitated using ammonium 
sulphate, then purified by sequential protein G and 
protein A lectin affinity chromatography.  Concentration 
of purified proteins was determined by UV–
spectrophotometry. The protein content of IgG1 after 
purification was 1.38 mg/ml. The content of Heavy 
Chain Antibodies (HCAbs) was 1.29 mg/ml and 1.30 
mg/ml for IgG2 and IgG3 respectively (Table 1).  The 
yield of HCAbs was nearly twice that of conventional 
IgG1. 
The purified antibody fractions were further 
characterized on SDS-PAGE and Western Blot. The 8% 
resolving gels were stained with Coomassie brilliant 
blue and PVDF membranes developed using a 
chemiluninescent substrate.  Under reducing 
conditions, camel IgG1 had two bands at approximately 
50 kd and 30 kd. The HCAbs showed single bands at 46 
kd and 43 kd for IgG2 and IgG3 respectively. 
Limit of detection of Chikungunya virus by antigen 
detection ELISA 
To determine the analytical limit of detection, 
inactivated Chikungunya virus antigen was diluted and 
analyzed by antigen detection ELISA. GraphPad Prism 
non-linear regression sigmoidal dose response curve 
model was used to fit the curve (Figure 2). For HCAb 
IgG2, the end point of titration corresponded to a limit 
of detection of 12 ng/ml, with a dynamic range 
0.012μg/ml to 31.6μg/ml. For HCAb IgG3 the limit of 
detection was 10 ng/ml, with a dynamic range 
0.01μg/ml to 63.1μg/ml. 
Figure 1: Immune responses of male and female camels to CHIKV immunogen. 
 
Table 1: Yield of purified immunoglobulin G sub-classes 
Immunoglobulin G subclass Yield (mg/ml serum) Relative yield (% total) 
IgG1 1.38 34.8 
IgG2 1.29 32.5 
IgG3 1.30 32.7 
 
Precision of Chikungunya virus antigen detection 
ELISA 
The precision of antigen detection ELISA was 
determined by testing spiked samples to calculate intra-
plate coefficient of variation (CV).  The same assay was 
performed 6 times (n=6) over a period of 2 months to 
estimate the coefficients of variation. The intra-plate CV 
was within 5% for different dilutions and the inter-plate 
CV within 8% for both IgG2 and IgG3 (Table 2). 
Sensitivity of CHIKV detection by HCAb-based IgM 
Capture ELISA 
A comparative analysis of the diagnostic performance of 
the developed HCAb-based IgM Capture ELISA against 
that of the CDC IgM Capture ELISA was carried out.   The 
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following parameters were determined: sensitivity, 
specificity, positive predictive value and negative 
predictive values.  
Sensitivity was defined as the ability of the assay to 
correctly detect specimens containing anti-CHIKV IgM 
antibodies, that is the percentage of true positive 
samples identified by the assay under evaluation as 
positive (TP), divided by the number of samples 
identified by the reference assay as positive (TP+FN). 
The sensitivity of the dromedary HCAb IgG2 assay was 
91.3% (95% CI: 0.831-0.994); while that for HCAb IgG3 
assay was 95.7% (95% CI: 0.898-1.01) (Table 3 and 4). 
Figure 2: Limit of detection of HCAb IgG2 (A) and IgG3 (B) Assays 
 
   Table 2: Precision of CHIKV antigen detection ELISA   
Concentration of CHIKV 
Antigen (μg/ml) 
Intra-Assay Coefficient of 
Variation (%CV) 
 Inter-Assay Coefficient of 
Variation (%CV) 
HCAb IgG2 HCAb IgG3  HCAb IgG2 HCAb IgG3 
0.01 2.91 3.72  4.45 6.51 
0.1 1.87 2.51  4.23 5.6 
1.0 2.63 2.86  3.94 4.78 
10 3.53 2.96  5.11 7.34 
100 4.21 4.57  7.67 7.89 
 
   Table 3: Comparison of the performance of dromedary HCAb IgG2 ELISA with the reference test 
HCAb IgG2 Results 
Reference Standard Results 
Total 
Positive Negative 
Positive 42 11 53 
Negative 4 131 135 
Total 46 142 188 
 
   Table 4: Comparison of the performance of dromedary HCAb IgG3 ELISA with the reference test 
HCAb IgG3 Results 
Reference Standard Results 
Total 
Positive Negative 
Positive 44 14 58 
Negative 2 128 130 
Total 46 142 188 
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Analytical Specificity 
Analytical specificity was defined as the ability of the 
assay to correctly detect samples that do not contain 
anti-CHIKV IgM antibodies. Specificity was calculated as 
the percentage of true negative specimens identified by 
the assay being evaluated as negative (TN), divided by 
the number of specimens identified by the reference 
assays as negative (TN + FP). 
The specificity of HCAb IgG2 assay was 92.3% (95% CI: 
0.879-0.967); while the specificity of HCAb IgG3 method 
was 90% (95% CI: 0.851-0.949) (Table 3 and 4). 
Positive Predictive Value (PPV) 
The probability that when the test was reactive, the 
sample actually contained anti-CHIKV IgM antibodies, 
that is, the positive predictive value, was determined 
from the formula TP/TP + FP. For HCAB IgG2 and IgG3 
based assays, the positive predictive values were 79.2% 
and 75.8 % respectively.   
Negative Predictive Value (NPV) 
The probability that when the test was negative, the 
sample did not have anti-CHIKV IgM antibodies, the 
negative predictive value, was determined from the 
formula: TN/FN+TN. The negative predictive values 
were 97% and 98.4% for HCAb IgG2 and IgG3 based 
assays respectively. 
4.0 Discussion 
In this study, dromedary antibody-based enzyme linked 
immunosorbent assay for detecting Chikungunya virus 
infections was developed, optimized and validated. Our 
findings demonstrate that camel heavy chain antibody-
based immunoassays are reliable tools for the diagnosis 
of Chikungunya virus infections, with dromedary HCAb 
IgG2 and HCAb IgG3 showing sensitivities of 91.3% and 
95.7% respectively. Previous studies have 
demonstrated relatively low sensitivity in a number of 
commercially available kits.  In a Sri Lankan study two 
commercial Chikungunya virus  IgM tests had a sample 
sensitivities of only 3.9 %  (Blacksell et al, 2011).  Low 
sensitivity was also found with two commercial 
immunochromatographic tests: OnSite and SD Bioline 
CHIKV IgM rapid tests assessed in Indonesia.  The 
sensitivity of OnSite was only 20.5%, while that of SD 
Bioline was 50.8% (Kosasih et al, 2012).  Two 
commercial kits have however shown high sensitivity 
during field testing. The Euroimmun ELISA and Abcam 
Anti-CHIKV IgM human ELISA kits obtained 99% 
concordance with the CDC reference ELISA test 
(Johnson et al, 2016). The sensitivity of the kits was 
however reduced at high dilutions of patient sera. 
The sensitivity of tests can be affected by the genetic 
differences of the virus used for preparing the 
immunogen (Kosasih et al, 2012). In this project, the 
viral immunogen was prepared from a phylogroup that 
circulated in Kenya in 2004, that is Chikungunya virus 
strain Lamu 33. Nonetheless, the reference assay (CDC 
IgM ELISA) was developed based on CHIKV strain S27, 
the African prototype CHIKV strain, and this can explain 
the lack of 100% concordance.  The time at which the 
serum is collected following illness can also determine 
the sensitivity of the assay. IgM antibodies against 
CHIKV reach detectable levels 4 -7 days following 
infection. It is therefore possible to get a false negative 
result, depending on the time of sera collection. Sera 
collected at early acute phases may therefore give false 
negative results (Pialoux et al, 2007). This too may 
explain the lack of 100% concordance of our results. 
The diagnostic specificity of the camel HCAb IgG2 and 
IgG3 assays, when compared against the reference test 
was 92.3% and 90% respectively. This was high, and 
concords with results reported in literature for some 
commercial tests.  Blacksell et al (2011), in a Sri Lankan 
study, found two commercial  CHIKV  IgM tests had 
diagnostic specificities of 92.5 and 95.0%.  
Similarly, in an Indonesian field testing, Kosasih et al 
(2012) found OnSite and SD Bioline Chikungunya  IgM 
immunochromatographic tests to have specificities of 
100% and 89.2% respectively.  In a review of literature, 
Sam et al (2011), reported that the specificity of most 
commercial kits range between 90-100%. The 
specificity of the assay developed in this study is 
therefore acceptable.  
It is however notable that IgM antibodies against CHIKV 
may persist for up to 2 years following viral infection, 
with the possibility of giving a false positive result 
(Grivard et al, 2007). This would be expected to become 
a diagnostic challenge should CHIKV become endemic in 
certain areas of Kenya. 
Additionally, the experimental camels demonstrated 
robust immune responses; and purification of the 
antibodies were achieved with high yields in sequential 
steps of  ammonium sulphate precipitation, followed by 
lectin affinity chromatography on protein A and protein 
G columns.    The HCAbs constituted 65% of the IgG in 
camel serum, a finding consistent with previous studies 
which have shown that in llamas and camels, HCAbs 
constitute 50 -75% of serum IgGs (Daley, 2007). 
5.0 Conclusion  
Overall, the developed camel antibody based enzyme 
linked immunosorbent assays were shown to be 
reliable, sensitive, and accurate and will be invaluable in 
the detection of Chikungunya virus infections. The 
assays demonstrated high precision with the intra-plate 
CV is within 5% for different dilutions and the inter-
plate CV is within 8% for both HCAb IgG2 and IgG3 
based assays. 
While this work is innovative in using purified 
subclasses of HCAb for development of immunoassays, 
future areas of work include testing the assays in field 
situations where infections with different phylogroups 
of Chikungunya virus are present. Another area that 
requires further development is miniaturization of the 
tests for rapid diagnostics such as deployment of the 
HCAbs in immunochromatographic strips. 
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